$CAPR

2 stories mentioning CAPRUpdated just now

Every FINWIRES story that references CAPR, newest first.

B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63

Capricor Therapeutics (CAPR) has an average rating of buy and mean price target of $45.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CAPR

Research3h ago

Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38

Capricor Therapeutics (CAPR) has an average rating of Buy and mean price target of $45.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CAPR

Track with the FINWIRES app suite

FolioX

Track CAPR in your portfolio

WheelAI

Analyze CAPR options with the wheel strategy

StockInsider

See market sentiment on CAPR